Skip to main content

Neal Flomenberg

Equibles does not estimate personal net worth.

Get an email with a short summary when Tevogen Inc. publishes a filing, an earnings call transcript or a press release.

Get TVGN alerts

About Neal Flomenberg

Tevogen Inc. reported in an 8-K filed February 14, 2024 that Neal Flomenberg was appointed Chief Scientific Officer and Global R&D Lead, effective February 14, 2024. The proxy statement of Tevogen Inc. reports total compensation of $722,000 for Neal Flomenberg in fiscal 2025, including a base salary of $350,000. Disclosed compensation is on record for 3 fiscal years. Tevogen Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tevogen Inc. includes Dr. Ryan Saadi (CEO and Board Member), Ryan Saadi (CEO and Chairman), Surendra Ajjarapu (CEO and Board Member) and 7 others.

“The following persons are serving as executive officers and directors of the Company effective as of the Closing Date, with each of the directors having been elected by the Semper Paratus stockholders and each of the executive officers having been appointed by the Semper Paratus Board, and ratified by the Tevogen Board, effective as of the Closing Date.”
Tevogen Inc. Form 8-K, filed February 14, 2024 · Read the filing

Affiliation history

Company network

Leadership on record at Tevogen Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Tevogen Inc. (TVGN) $350,000 $722,000
2024 Tevogen Inc. (TVGN) $350,000 $350,000
2023 Tevogen Inc. (TVGN) $350,000 $2,926,000

Recent activity